Claims
- 1. A retroviral vector comprising, 5′ to 3′ and in operable linkage, a 5′ long terminal repeat (LTR), a splice donor, a packaging sequence, a gag open reading frame (ORF) mutated to reduce translation of gag peptides, a splice acceptor, a start codon in frame with a DNA sequence and a 3′ LTR.
- 2. The vector according to claim 1 wherein said vector further comprises a multiple cloning site (MCS) in said 3′ LTR.
- 3. The vector according to claim 1, wherein said packaging signal is an extended N2-derived packaging signal.
- 4. The vector according to claim 1 wherein said splice signals are wild type retroviral splice signals.
- 5. The vector according to claim 1 wherein said start codon is viral env ATG.
- 6. The vector according to claim 1 wherein said mutation in said gag ORF is an ATG to TAG mutation.
- 7. The vector according to claim 1 wherein said vector further comprises a polyadenylation signal 3′ to said 3′ LTR.
- 8. The vector according to claim 1 wherein said DNA sequence encodes an RNA antisense sequence or an RNA that is a DNA or RNA binding protein recognition sequence.
- 9. The vector according to claim 1 wherein said DNA sequence encodes an RNA antisense sequence.
- 10. The vector according to claim 9 wherein said RNA antisense sequence is complementary to a nucleotide sequence encoded in the genome of a pathogen.
- 11. The vector according to claim 10 wherein said pathogen is a bacteria or virus.
- 12. The vector according to claim 11 wherein said pathogen is human immunodeficiency virus.
- 13. The vector according to claim 1 wherein said DNA sequence encodes a polypeptide or protein.
- 14. The vector according to claim 13 wherein the polypeptide or protein is a mammalian polypeptide or protein.
- 15. The vector according to claim 1 wherein the DNA sequence encodes a selectable or identifiable phenotypic trait.
- 16. A method of producing an infectious viral particle comprising transfecting the retroviral vector of claim 1 into a retroviral packaging cell line under conditions such that said viral particle is produced, and recovering the viral particle.
- 17. A viral particle produced by the method of claim 16.
- 18. A packaging cell comprising the retroviral vector according to claim 1.
- 19. A method of introducing a transcription unit into a eucaryotic cell comprising infecting the cell with the viral particle according to claim 17.
- 20. The method according to claim 19 wherein said cell is a mammalian cell.
- 21. The method according to claim 20 wherein said cell is a human cell.
- 22. The method according to claim 21 wherein said cell is present in a human.
- 23. A isolated eucaryotic cell produced by the method of claim 19.
- 24. A pharmaceutical composition comprising the vector according to claim 1, a packaging cell comprising said vector or a viral particle produced by said packing cell, or a eucaryotic cell infected with said viral particle, and a carrier, diluent, adjuvant or excipient.
Parent Case Info
[0001] This application claims priority from U.S. Provisional Application No. 60/265,123, filed Jan. 31, 2001, the entire content of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60265123 |
Jan 2001 |
US |